SELLAS Life Sciences Group, Inc. (SLS)

NCM – Real Time Price. Currency in USD

5.22

-0.03 (-0.57%)

At close: May 12, 2026, 4:00 PM EDT

6.06

+0.84 (16.09%)

After-hours: May 12, 2026, 7:59 PM EDT

12.05.2026

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes – – Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80 th Event – – Ongoing Dosing of Patients in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML – – $107.1 Million in Cash and Cash Equivalents as of March 31, 2026; Additional $7.5 Million in Proceeds Received in Q2 2026 to Date through Warrant Exercises – NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. “The first quarter of 2026 marked an important period for SELLAS as we continued to execute across our clinical programs while preparing for the anticipated pivotal Phase 3 REGAL trial data readout,” said Angelos Stergiou, MD, ScD h.c.

23.04.2026

Sellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key Event

SELLAS Life Sciences is rated 'Hold' due to pending phase 3 REGAL data for GPS in AML after CR2, a major 2026 catalyst. The company's GPS targets WT1 in AML, with prior phase 1/2 data showing a median OS of 21 months versus 5.4 months for standard therapy. Interim REGAL analysis showed fewer than 50% deceased at 13.5 months; final analysis at 80 events expected in 1H 2026.

20.04.2026

Wall Street Analysts Think SELLAS Life Sciences Group, Inc. (SLS) Could Surge 66.09%: Read This Before Placing a Bet

The mean of analysts' price targets for SELLAS Life Sciences Group, Inc. (SLS) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

27.03.2026

These 16 stocks are a short seller's dream — likely losers no matter what the market does

Borrowing costs eat into trading profits. These stocks are less expensive to short.

26.03.2026

All You Need to Know About SELLAS Life Sciences Group, Inc. (SLS) Rating Upgrade to Buy

SELLAS Life Sciences Group, Inc. (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

26.03.2026

Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to Trade

The consensus price target hints at a 63.6% upside potential for SELLAS Life Sciences Group, Inc. (SLS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

20.03.2026

SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths

A late-stage clinical biopharmaceutical company focused on immunotherapy for various cancers, SELLAS Life Sciences Group ( NASDAQ:SLS ) is at a genuinely unusual inflection point.

Videos

No Data

There is no data to display

Press releases

12.05.2026

SELLAS Life Sciences Group, Inc. (SLS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

SELLAS Life Sciences Group, Inc. (SLS)

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Sellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key Event

Wall Street Analysts Think SELLAS Life Sciences Group, Inc. (SLS) Could Surge 66.09%: Read This Before Placing a Bet

These 16 stocks are a short seller's dream — likely losers no matter what the market does

All You Need to Know About SELLAS Life Sciences Group, Inc. (SLS) Rating Upgrade to Buy

Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to Trade

SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths

Videos

No Data

Press releases

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Sellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key Event

Wall Street Analysts Think SELLAS Life Sciences Group, Inc. (SLS) Could Surge 66.09%: Read This Before Placing a Bet

These 16 stocks are a short seller's dream — likely losers no matter what the market does

All You Need to Know About SELLAS Life Sciences Group, Inc. (SLS) Rating Upgrade to Buy

Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to Trade

SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths

Videos

No Data

Press releases

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

Search stocks

SELLAS Life Sciences Group, Inc. (SLS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

SELLAS Life Sciences Group, Inc. (SLS)

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Sellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key Event

Wall Street Analysts Think SELLAS Life Sciences Group, Inc. (SLS) Could Surge 66.09%: Read This Before Placing a Bet

These 16 stocks are a short seller's dream — likely losers no matter what the market does

All You Need to Know About SELLAS Life Sciences Group, Inc. (SLS) Rating Upgrade to Buy

Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to Trade

SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths

Videos

No Data

Press releases

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Sellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key Event

Wall Street Analysts Think SELLAS Life Sciences Group, Inc. (SLS) Could Surge 66.09%: Read This Before Placing a Bet

These 16 stocks are a short seller's dream — likely losers no matter what the market does

All You Need to Know About SELLAS Life Sciences Group, Inc. (SLS) Rating Upgrade to Buy

Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to Trade

SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths

Videos

No Data

Press releases

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe